InvestorsHub Logo
Followers 248
Posts 14923
Boards Moderated 0
Alias Born 05/06/2001

Re: None

Friday, 09/08/2023 7:48:59 AM

Friday, September 08, 2023 7:48:59 AM

Post# of 249
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
September 08 2023 - 07:00AM
GlobeNewswire Inc.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023.
“The NeuBase Board of Directors (“Board”) appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on maximizing shareholder value. The Board does not believe that shareholder value will be enhanced by issuing the special $1 per share dividend Symetryx requested in their press release. The Board and management will continue to seek an open and active dialogue with its shareholders, including Symetryx.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NBSE News